Abstract: This paper presents the design of novel 4-hydroxy-chromene-2-one derivatives, based on previously obtained minimal inhibitory concentration values (MICs), against twenty four microorganism cultures, Gram positive and negative bacteria and fungi. Two of our compounds, 3b (MIC range 130–500 μg/mL) and 9c (31.25–62.5 μg/mL), presented high potential antimicrobial activity. The compound 9c had equal activity to the standard ketoconazole (31.25 μg/mL) against M. mucedo. Enlarged resistance of S. aureus, E. coli and C. albicans on the effect of potential drugs and known toxicity of coumarin antibiotics, motivated us to establish SAR and QSAR models of activity against these cultures and correlate biological activity, molecular descriptors and partial charges of functional groups to explain activity and use for the design of new compounds. The QSAR study presents essential relation of antimicrobial activity and dominant substituents, 4-hydroxy, 3-acetyl and thiazole functional groups, also confirmed through molecular docking. The result was ten new designed compounds with much improved predicted inhibition constants and average biological activity.

Keywords: 4-hydroxy-coumarins; antimicrobial activity; QSAR; molecular docking; design
1. Introduction

Coumarins are known potential growth inhibitors of bacteria and fungi, where both natural and synthetic coumarins inhibit growth of common microorganisms *Candida albicans*, *Escherichia coli* and *Staphylococcus aureus* [1–5]. Some coumarin polyacetylene derivatives have antimycobacterial activity against *Mycobacterium fortituum* [6], while others inhibit IQ induced mutation in *S. typhimurium* TA98 [7]. Plant coumarins present antimicrobial potential too [8,9].

The nature of substituents define coumarin activity, and coumarin substitution in positions 3 and 7 is dominant for antimicrobial activity [10]. Our interest is in 3-acetyl and 3-thiazole 4-hydroxy-coumarin derivatives. Beside the known antimicrobial activity [11] of 3-acetyl coumarin derivatives, the presence of thiazole functional group indicates antihelmintic, antibiotic and immunosuppressant activity of a potential drug [12].

While the exact mechanism of coumarin-based microorganism growth inhibition is not yet certain, the 24 kDa N-terminal domain of DNA gyrase B subunit (p24), an enzyme that unwinds double stranded DNA of microorganisms, causing the supercoiling of the DNA, is recognized as the molecular target of natural occurring coumarins like novobiocin and clorobiocin [13] that inhibit the ATPase activity of the B subunit. These drugs have a 4-hydroxycoumarin core in common, which is substituted at the 7 and 3 positions [13]. In p24/novobiocin complex, coumarin ring forms only two hydrogen bonds, both with Arg136 interacting with carbonyl and lactone oxygen [13], while the main interactions occur between p24 and novobiose residue [13].

As a result of their varied biological activity, qualitative (SAR) and quantitative structural-activity relationship (QSAR) studies of isolated and synthetic coumarin derivatives are widespread nowadays. Computational studies, which are principals of QSAR, had been performed regarding the molecular lipophilicity [14] and cytotoxic activity [15] of different 4-hydroxycoumarin derivatives. The antimicrobial activity against *S. aureus* and *C. albicans* [16] of some 3-acyl-4-hydroxy and 3-nitrocoumarins has been explained by QSAR, using both semi empirical and density functional theory (DFT) based calculations. Some thiazole coumarin derivatives and their activity against *C. albicans*, *E. coli* and *S. aureus* were the subject of QSAR determination, too [12].

Due to the mentioned activity of carbonyl and thiazole functional groups, we used a synthesized series of carbonyl, carboxyl and thiazole coumarin derivatives (Scheme 1) [3,4] and evaluated their activity through calculated molecular properties and partial atomic charges of potential functional groups, in attempt to explain their bioactivity as antimicrobial agents against Gram positive and negative bacteria and fungus.

Our interest in SAR and QSAR studies of synthetic coumarins started with the examination of the antimicrobial activity of our derivatives [3,4] whereby they presented growth inhibition potential on a wide spectrum of cultures. We decided to perform QSAR evaluation of cultures like *Staphylococcus aureus* (ATCC 25925), *Escherichia coli* (ATCC 25922) and *Candida albicans* (ATCC 10259), for the future design of new more power derivatives. Certain compounds, 3b [3] and 9c [4] that displayed both enhanced antibacterial and antifungal activities, can be the base for lead optimization and simple but efficient design of new compounds.
2. Results and Discussion

2.1. Antimicrobial activity

SAR and QSAR methodology were used to explain the antimicrobial activity of the synthesized coumarin derivatives, 1-10c (Figure 1), on a wide spectrum of the cultures.

Figure 1. Synthesized 4-hydroxy-coumarin derivatives.

Table 1. Antimicrobial activity of synthetic coumarin derivatives.

| Comp. | S. aureus | E. coli | C. albicans |
|-------|-----------|---------|-------------|
|       |         | MIC\(^a\) values of tested compounds (10\(^{-6}\) g/mL) (-log MIC) |         |         |
|       | Experimental | Calculated | Experimental | Calculated | Experimental | Calculated |
| 1     | 90 ± 0.35 (4.046) | 103 (3.984) | 190 ± 0.35 (3.721) | 195 (3.708) | 90 ± 0.05 (4.046) | 92 (4.035) |
| 3b    | 130 ± 0.22 (3.886) | 156 (3.806) | 130 ± 0.34 (3.886) | 132 (3.878) | 130 ± 0.15 (3.886) | 130 (3.885) |
| 4b    | 130 ± 0.50 (3.886) | 222 (3.652) | 130 ± 0.25 (3.886) | 129 (3.888) | 250 ± 0.25 (3.602) | 132 (3.878) |
| 6b    | 130 ± 0.45 (3.886) | 116 (3.932) | 250 ± 0.55 (3.602) | 255 (3.592) | 130 ± 0.15 (3.886) | 129 (3.889) |
| 7b    | 130 ± 0.35 (3.886) | 112 (3.947) | 500 ± 0.35 (3.301) | 519 (3.284) | 500 ± 0.35 (3.301) | 124 (3.908) |
| 8b    | 130 ± 0.26 (3.886) | 136 (3.865) | 130 ± 0.35 (3.886) | 117 (3.932) | 130 ± 0.55 (3.886) | 130 (3.886) |
| 2c    | 125 ± 0.25 (3.904) | 62.5 (4.206) | 250 ± 0.55 (3.602) | 491 (3.309) | 62.5 ± 0.55 (4.204) | 137 (3.862) |
| 3c    | 125 ± 0.25 (3.904) | 60 (4.217) | 62.5 ± 0.25 (4.204) | 62.5 (4.204) | 62.5 ± 0.55 (4.204) | 145 (3.893) |
| 4c    | 62.5 ± 0.29 (4.204) | 62.5 (4.204) | 62.5 ± 0.10 (4.204) | 62.6 (4.203) | 62.5 ± 0.15 (4.204) | 63 (4.205) |
| 5c    | 62.5 ± 0.24 (4.204) | 33.5 (4.475) | 125 ± 0.50 (3.904) | 124 (3.906) | 31.25 ± 0.10 (4.505) | 63 (4.205) |
| 6c    | 250 ± 0.35 (3.602) | 66 (4.179) | 125 ± 0.35 (3.904) | 125 (3.902) | 62.5 ± 0.15 (4.204) | 234 (3.630) |
| 7c    | 250 ± 0.55 (3.602) | 26.2 (4.581) | 125 ± 0.45 (3.904) | 131 (3.884) | 31.25 ± 0.55 (4.505) | 245 (3.610) |
| 8c    | 250 ± 0.36 (3.602) | 121 (3.914) | 250 ± 0.12 (3.602) | 214 (3.670) | 125 ± 0.15 (3.904) | 262 (3.582) |
| 9c    | 31.25 ± 0.21 (4.505) | 30 (4.526) | 62.5 ± 0.09 (4.204) | 63.1 (4.200) | 31.25 ± 0.25 (4.505) | 31 (4.508) |
| 10c   | 125 ± 0.38 (3.903) | 69.5 (4.158) | 125 ± 0.25 (3.904) | 141 (3.851) | 62.5 ± 0.55 (4.204) | 118 (3.928) |
| S     | 31.25 ± 0.07 | 31.25 ± 0.35 | 31.25 ± 0.07 | 31.25 ± 0.35 | 31.25 ± 0.07 | 31.25 ± 0.35 |
| K     | 1.95 ± 0.05 | 1.95 ± 0.05 | 1.95 ± 0.05 | 1.95 ± 0.05 | 1.95 ± 0.05 | 1.95 ± 0.05 |

\(^a\)Results are mean values SD from at least three experiments; \(^b\)S=streptomycin; \(^c\)K=ketoconazole.
Among the tested compounds, initial coumarin 1 and two structurally different groups of derivatives, first 2-8b, and second 2-10c, compounds 3b and 9c demonstrated enhanced activity, with MICs in the range of 130–500 and 31.25–62.5 μg/mL, respectively, due to influence of the C-3 coumarin scaffold, acetyl, carboxymethyl and thiazole-m-nitro substituents. The activities of 3b and 9c are explained by SAR, QSAR and molecular docking study on DNA gyrase, suggesting them as promising structures for lead optimization and design of new compounds. The carbonyl, carboxyl derivatives 1-8c, generally, did not presented the expected activity, but their SAR and QSAR studies emphasize the role of coumarin core in activity.

2.2. SAR

As presented by Table 1, compounds 2-10c (MIC range 31.25–500 μg/mL) [4] presented better antimicrobial activity than the compounds 1-8b (MIC range 90–940 μg/mL) [3]. The main difference in the biological activity of compounds is caused by the presence of thiazole function in 2-10c followed up with the great dissimilarity in MIC values. The basic compound 1 presented medium activity, with a MIC value of 90 μg/mL for S. aureus and C. albicans, and 190 μg/mL for E. coli. Regarding the overall activity of the first set of synthesized compounds (MIC 130–500 μg/mL), 3b is the most active one, presenting the same activity due to attendance of carbonyl and carboxyl functions, but lower than 1 against S. aureus and C. albicans (130 μg/mL), and better against E. coli and M. lysodeikicus (130 μg/mL). Compared with the reference antibiotics, the activity of 3b is still much reduced. The insertion of a 2-aminothiazole pharmacophore in the coumarin moiety overcame the low activity of compounds 1-8b and increased it several times. The most active compound, 9c, an m-nitro derivative, presented an equal MIC value to the reference antibiotic on M. mucido (31.25 μg/mL).

2.3. QSAR

The QSAR analysis was performed correlating the antimicrobial activity against S. aureus (ATCC 25925), E. coli (ATCC 25922) and C. albicans (ATCC 10259) presented in Table 1, with various physico-chemical parameters (Table 2) and partial charges (Table 3), to reveal predictions for the lead optimization in the training set of compounds of newly synthesized coumarins [3,4].

Table 2. Relevant calculated physico-chemical parameters of synthesized 4-hydroxy-coumarin derivatives.

| Comp. | log P | MR  | lipole | HOMO | LUMO | CAA  | CMA  | CSEV | ovality |
|-------|-------|-----|--------|------|------|------|------|------|---------|
| 1     | -0.529| 51.062| 2.161 | -9.989| -1.490| 335.170| 156.104| 124.411| 1.368 |
| 3b    | -1.318| 75.494| 1.622 | -10.015| -1.562| 466.977| 236.476| 203.327| 1.590 |
| 4b    | -0.035| 66.062| 1.646 | -9.958| -1.537| 424.305| 205.095| 165.182| 1.495 |
| 6b    | -1.679| 75.277| 1.905 | -9.977| -1.453| 444.049| 223.344| 192.322| 1.561 |
| 7b    | -1.765| 67.538| 2.645 | -10.040| -1.646| 424.466| 207.570| 171.656| 1.482 |
| 8b    | -1.709| 66.570| 2.507 | -10.037| -1.694| 426.269| 208.634| 173.406| 1.512 |
| 2c    | 1.216 | 96.238| 0.557 | -9.042| -1.449| 566.431| 291.664| 246.339| 1.645 |
| 3c    | 3.129 | 95.320| 2.244 | -9.003| -1.954| 542.789| 279.873| 233.719| 1.604 |
| 4c    | 0.702 | 65.468| 1.415 | -8.999| -1.621| 572.035| 296.286| 249.537| 1.654 |
Table 2. Cont.

|   | 5c  | 6c  | 7c  | 8c  | 9c  | 10c |
|---|-----|-----|-----|-----|-----|-----|
|   | 2.904 | 95.722 | 2.513 | -8.900 | -1.135 | 521.823 |
|   | 1.921 | 88.488 | 0.281 | -8.923 | -0.936 | 552.855 |
|   | 1.856 | 84.807 | 1.112 | -8.890 | -0.950 | 478.322 |
|   | 3.380 | 93.722 | 2.552 | -8.913 | -0.659 | 521.339 |
|   | 3.129 | 95.320 | 2.101 | -8.972 | -1.759 | 538.849 |
|   | 3.603 | 104.966 | 3.169 | -8.866 | -1.231 | 558.547 |

Table 3. Partial atomic charges of the compounds 1-8b and 2-10c.

| Functional groups | 1  | 3b | 4b | 6b | 7b | 8b |
|-------------------|----|----|----|----|----|----|
| 4-OH              | -0.615 | -0.646 | -0.637 | -0.648 | -0.614 | -0.625 |
| O-lactone         | -0.523 | -0.523 | -0.522 | -0.522 | -0.515 | -0.515 |
| CO-lactone        | -0.474 | -0.491 | -0.493 | -0.491 | -0.473 | -0.464 |
| CO                | -0.456 | -0.609 | -0.604 | -0.613 | -0.531 |       |
| CO-carboxyl       | 0.221  | 0.235  | 0.225  |       |       |       |
| OH-carboxyl       | -0.507 | -0.492 | -0.579 | -0.586 |       |       |
| CN                | -0.452 | -0.463 | -0.475 |       |       |       |
| Functional groups | 2c | 3c | 4c | 5c | 6c | 7c | 8c | 9c | 10c |
| 4-OH              | -0.638 | -0.644 | -0.204 | -0.617 | -0.675 | -0.671 | -0.646 | -0.637 | -0.648 |
| O-lactone         | -0.522 | -0.520 | -0.114 | -0.599 | -0.531 | -0.532 | -0.523 | -0.522 | -0.522 |
| CO-lactone        | -0.492 | -0.490 | -0.195 | -0.499 | -0.515 | -0.516 | -0.491 | -0.493 | -0.491 |
| N-thiazole        | -0.582 | -0.604 | -0.261 | -0.681 | -0.673 | -0.659 | -0.609 | -0.604 | -0.613 |
| S-thiazole        | 0.230  | 0.244  | 0.296  | 0.458  | 0.261  | 0.259  | 0.221  | 0.235  | 0.225  |
| N-amine           | -0.750 | -0.744 | -0.262 | -0.753 | -0.610 | -0.419 | -0.743 | -0.747 | -0.745 |
| CO-carboxyl       | -0.467 |       |       |       |       |       |       |       |       |
| OH-carboxyl       | -0.582 |       |       |       |       |       |       |       |       |
| OH-phenyl         | -0.638 |       |       |       |       |       |       |       |       |
| N-nitro           | -0.374 |       |       |       |       |       |       |       | -0.386 |
| O-nitro           | -0.400^b |       |       |       |       |       |       | -0.392^b | -0.386^b |
| S-SO_3H           | 0.758  |       |       |       |       |       |       |       |       |
| O-SO_3H           | -0.282^c |       |       |       |       |       |       | 0.259^c |       |
| OH-SO_3           |       |       |       |       |       |       |       |       | -0.256 |

^aTwo carbonyl groups in compound 6b; ^bTwo O-nitro atoms in compounds 3c and 10c; ^cTwo O-SO_3H atoms in compound 4c.

Although this set is small, it provides QSAR equations that could be statistically significant for the activity against *S. aureus*, *E. coli* and *C. albicans*. The results of regression analysis are shown in Eqns. (1), (2) and (3) and by Figures 2(a) and (b) and 3, where *n* is number of molecules, *r* is correlation, *F* is Fisher’s significance factor and *s* is standard deviation. Cross-validation resulted with Q^2 as the square of predictive power of coefficient and s-PRESS as predictive residual sum of squares.

The model 1 defines the *N*-thiazole atom as important in the interaction of coumarin with bacteria. For the activity against *S. aureus*, the solubility factor is irrelevant. Regarding the model 2, besides the
N-thiazole atom, the antimicrobial activity against \(E. \text{coli}\) depends on interactions with the 4-OH group and S-thiazole atom, with solubility and LUMO energy as important factors. The solubility factor is expected referring to Table 2, for it the training set presents wide range in solubility, from the most hydrophilic (-1.765) to the most hydrophobic (3.603) compounds.

The 4-OH and S functional groups do not take the same part in antibacterial activity of \(9c\) in model 2, with correlation factors between biological activity and charge \(r_{4-OH} = 0.603\) and \(r_S = 0.942\). The LUMO energy factor suggests that charge transfer might be involved in the mechanism of action [17]. As mentioned, the main factor in the activity is the \(N\)-thiazole atom, with a correlation \(r = 0.674\) of charge and antimicrobial activity of \(9c\). Both QSAR equations (1) and (2) for activity against \(S. \text{aureus}\) and \(E. \text{coli}\) are statistically very significant with \(F=104.2987, r (99.7\%) [\text{Figure 1 (a)}]\) and \(F=28.8394, r (99.5\%) [\text{Figure 1 (b)}]\), respectively.

**QSAR model for activity against \(S. \text{aureus} \) (model 1):**

\[
- \log MIC = 18.2669( \pm 2.82) - 0.0701( \pm 0.01) \times MR - 0.3670( \pm 0.03) + 1.0871( \pm 0.30) \\
\times \text{HOMO} - 0.1682( \pm 0.01) \times \text{CAA} - 0.5095( \pm 0.02) \times \text{CMA} - 7.8116( \pm 0.76) \times \text{O-lactone} + 1.6749( \pm 0.44) \times \text{N-thiazole} - 1.4266( \pm 0.23) \times \text{S} - 0.2159( \pm 0.01) \times \text{CSEV} \tag{1}
\]

\(n=15 \, r=0.997 \, s=0.03 \, F=104.2987 \, Q^2=0.995 \, s\text{-PRESS}=0.005\)

**QSAR model for activity against \(E. \text{coli} \) (model 2):**

\[
- \log MIC = 18.5685( \pm 1.95) + 0.9195( \pm 0.12) \times \log P - 0.1766( \pm 0.04) \times \text{lipole} - 0.8233( \pm 0.15) \times \text{virtual log } P + 1.0722( \pm 0.12) \times \text{LUMO} - 0.0270( \pm 0.01) \times \text{CAA} + 7.0623( \pm 1.39) \times 4\text{-OH} - 8.4340( \pm 1.84) \times \text{CO-lactone} - 1.4566( \pm 0.69) \times \text{NH} + 1.7931( \pm 0.81) \times \text{N-thiazole} - 0.6662( \pm 0.47) \times \text{S} - 22.4376( \pm 1.83) \times \text{ovality} \tag{2}
\]

\(n=15 \, r=0.995 \, s=0.059 \, F=28.8394 \, Q^2=0.991 \, s\text{-PRESS}=0.011\)

**Figure 2.** Plot of observed vs. calculated – log MIC values of the training set compounds obtained from a) Equation (1), b) Equation (2).

**QSAR model for activity against \(C. \text{albicans} \) (model 3):**

\[
- \log MIC = -3.3032( \pm 1.43) + 0.9667( \pm 0.10) \times \log P - 1.1485( \pm 0.13) - 0.5781( \pm 0.10) \times \text{LUMO} - 0.054( \pm 0.01) \times \text{CAA} + 0.0713( \pm 0.01) \times \text{CMA} - 0.6944( \pm 0.24) \times 4\text{-OH} + 1.2423( \pm 0.31) \times \text{S} + 10.2506( \pm 1.41) \times \text{ovality} \tag{3}
\]

\(n=15 \, r=0.991 \, s=0.068 \, F=42.6548 \, Q^2=0.983 \, s\text{-PRESS}=0.028\)
Figure 3. Plot of calculated vs. observed – log MIC values of the training set compounds obtained from Equation (3).

Antifungal activity against *C. albicans*, equation Eqn. (3), can be explained by influence of solubility [18], electronic (LUMO) and steric (CMA) parameters. The positive impact of the S-thiazole atom on QSAR model 3 confirms the thiazole group as the most important one in the coumarin derivatives’ activity. The lower (model 3) or even no (model 1) influence of 4-OH might indicate a different coumarins-fungus mechanism of interaction compared to the coumarin-bacteria one (model 2). The goodness-of-fit of equation (3) (Figure 2) is very significant, possessing a high $r$ (99.1%) and a small $s$ (0.068) with an overall $F$ test value of 42.6548 at the significant level of $p < 0.05$. The correlation matrix of biological activity with molecular descriptors is presented in Table 4.

|   | D1  | D2  | D3  | D4  | D5  | D6  | D7  | D8  | D9  | D10 | D11 | D12 | D13 | D14 | bC1 | C2  | C3  |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| D1| 1.00|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| D2| 0.43| 1.00|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| D3| 0.35| 0.99| 1.00|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| D4| 0.39| 0.35| 0.25| 1.00|     |     |     |     |     |     |     |     |     |     |     |     |     |
| D5| 0.77| 0.54| 0.46| 0.45| 1.00|     |     |     |     |     |     |     |     |     |     |     |     |
| D6| 0.64| 0.59| 0.43| 0.46| 0.98| 1.00|     |     |     |     |     |     |     |     |     |     |     |
| D7| 0.35| 0.43| 0.47| 0.44| 0.96| 0.96| 1.00|     |     |     |     |     |     |     |     |     |     |
| D8| 0.56| 0.37| 0.11| 0.78| 0.37| 0.19| 0.23| 1.00|     |     |     |     |     |     |     |     |     |
| D9| 0.12| 0.06| 0.66| 0.12| 0.54| 0.43| 0.46| 0.00| 1.00|     |     |     |     |     |     |     |     |
| D10| 0.28| 0.95| 0.89| 0.23| 0.62| 0.61| 0.22| 0.94| 1.00|     |     |     |     |     |     |     |     |
| D11| 0.11| 0.72| 0.68| 0.27| 0.63| 0.64| 0.58| 0.36| 0.44| 1.00|     |     |     |     |     |     |     |
| D12| 0.29| 0.47| 0.34| 0.61| 0.15| 0.15| 0.19| 0.18| 0.19| 0.36| 1.00|     |     |     |     |     |     |
| D13| 0.36| 0.44| 0.95| 0.25| 0.31| 0.37| 0.31| 0.62| 0.55| 0.34| 0.95| 1.00|     |     |     |     |     |
| D14| 0.13| 0.78| 0.66| 0.14| 0.72| 0.74| 0.64| 0.15| 0.73| 0.78| 0.66| 0.23| 0.47| 1.00|     |     |     |
| C1| 0.045| 0.52| 0.94| 0.00| 0.44| 0.53| 0.57| 0.00| 0.84| 0.32| 0.36| 0.96| 0.66| 1.00|     |     |     |
| C2| 0.77| 0.00| 0.88| 0.94| 0.51| 0.53| 0.96| 0.54| 0.26| 0.58| 0.21| 0.19| 0.34| 0.55| 1.00|     |     |
| C3| 0.75| 0.00| 0.96| 0.12| 0.35| 0.15| 0.93| 0.24| 0.00| 0.00| 0.01| 0.52| 0.75| 1.00|     |     |     |

\(^a\)D1 log $P$; D2 MR; D3 HOMO; D4 LUMO; D5 CAA; D6 CMA; D7 CSEV; D8 ovality; D9 4-OH; D10 O-lactone; D11 CO-lactone; D12 NH; D13 N-thiazole; D14 S; \(^b\)C1 *S. aureus*; C2 *E. coli*; C3 *C. Albicans*. 

Table 4. Correlation matrix of biological activity with molecular descriptors.
The linear regression analysis of the activity of the most active compound, 9c, presents the correlation of \( m \)-nitro group and biological activity with the value of \( r = 0.902 \). This value is the highest correlation coefficient for partial charge found in this study and it overlaps with the microbiology and SAR results. The QSAR results are in high correlation with SAR and they confirmed the SAR statement that the thiazole ring is the key part for antimicrobial activity. The absence of carbonyl and carboxyl functions (compounds 1-8b) in the QSAR equations verified them as particularly unimportant for antimicrobial activity.

2.4. Molecular docking

Crystallographic data of the binding of novobiocin and chlorobiocin show four hydrogen bonds between novobiocine and p24 (Asn46, Gly50, Asp73), but only two between the enzyme and coumarin ring formed by lactone part and Arg136 [13]. We performed the molecular docking of 1, 3b and 9c to obtain interactions of our derivatives in active site of 24 kDa N-terminal domain of DNA gyrase B subunit and to explain the activity of the compounds, aiming interactions of C-3 scaffolds with Arg136 when grid box was set to cover the crucial amino acids for coumarin binding, i.e., Arg76, Pro79 and Arg136 [13].

Compound 1 forms with Arg136 only one hydrogen bond, between the lactone O atom of the coumarin ring and the NH\(_2\) guanido atom of Arg136. The activity of 3b (Figure 4) is expressed also with formation of one hydrogen (1.768 Å) bond with Arg136, formed by the carbonyl oxygen of the scaffold. Also, the guanido carbon forms with the C-5 coumarin carbon a pi-cation interaction. Predicted inhibition constant for 3b, \( K_i = 1.5 \text{ mM} \) versus the inhibition constant of 1, \( K_i = 3.67 \text{ mM} \), and the role of residue confirm SAR and QSAR interpretations of the higher activity of 3b related to 1.

![Figure 4. Molecular docking of compounds 3b and 9c.](image)

The most active compound, 9c (Figure 3), forms two hydrogen bonds, making the great difference in overall activity. The first one (2.027 Å) is between the lactone O atom and a new amino acid, Thr163, opposite to 1 and 3b. The second one (1.879 Å) is formed by the \( m \)-NO\(_2\) oxygen atom and Arg136, which is the final conformation of the high influence of thiazole-\( m \)-nitro system on activity of 9c, also
presented by SAR and QSAR. The sulfur from the thiazole ring forms ionic interactions with Gly 137. The orientations of Glu50, Arg76 and Pro79 around 1, 3b and 9c are similar to the ones around novobiocin, mostly forming hydrophobic interactions [13].

2.5. Design of novel coumarin derivatives

Based on obtained SAR, QSAR and molecular docking results, we designed ten new compounds with high improved predicted $K_i$ values and average antimicrobial activity. The design of new compounds, with the aim to remove the novobiose residue from antimicrobial activity of the coumarins and passing it on the C-3 scaffolds, had been performed respecting simple principles: introduction of hydroxyl group in C-7 position of the coumarin core, replacement of inactive b compounds 3-(prop-1-en-2-yl) function by nitrogen or sulfur more active residues, activation if inactive of carbonyl and carboxyl residues and retention or further modification of active pharmacophores learned by SAR and computational studies.

Figure 5. Designed 4-hydroxycoumarin derivatives.

![Chemical structures](image)

$1d$ $K_i = 7.87$ μM; $MIC = 10 \mu g/mL$

$2d$ $K_i = 23.06$ μM; $MIC = 15 \mu g/mL$

$3d$ $K_i = 428.36$ μM; $MIC = 25 \mu g/mL$

$4d$ $K_i = 38.96$ μM; $MIC = 10 \mu g/mL$

$5d$ $K_i = 96$ μM; $MIC = 25 \mu g/mL$

$6d$ $K_i = 128$ μM; $MIC = 18 \mu g/mL$

$8d$ $K_i = 284.54$ μM; $MIC = 15 \mu g/mL$

$9d$ $K_i = 47.55$ μM; $MIC = 15 \mu g/mL$

$10d$ $K_i = 275.18$ μM; $MIC = 7.5 \mu g/mL$

All the structures were optimized and docked according to described methods (Figure 6). The range of predicted average MIC was 3–25 μg/mL, far below the activity obtained by experiments. The most
active designed compound (Figure 6), 7d, with predicted $K_i = 90.06 \mu M$ and MIC = 3 $\mu g/mL$ forms with p24 one hydrogen bond (green line on Figure 6) between the $p$-N-acetyl oxygen and Thr165 (2.169 Å). Following compound, 1d, $K_i = 7.87 \mu M$ and MIC = 10 $\mu g/mL$, forms two hydrogen bonds with enzyme, between the carbonyl residue and Arg136 (2.185Å) and between 7-OH and Asp73 (1.653 Å). The increased number of hydrogen bonds formed by 2d, i.e., one 7-OH-Asp73 (2.072 Å) interaction and two interactions between Asp136 and external lactone ring oxygen atoms (1.779; 2.249 Å), could improve drug activity ($K_i = 23.06 \mu M$ and MIC = 15 $\mu g/mL$). The formation of hydrogen bonds between introduced 7-hydroxyl group (5d; $K_i = 96 \mu M$ and MIC = 25 $\mu g/mL$ and 6d; $K_i = 128 \mu M$ and MIC = 18 $\mu g/mL$, 1.788Å) and Asp73 and electrostatic interaction between the oxazole ring and Arg136 (6d) enlarge the antimicrobial potential, while only bonding 7-OH-Arg136 cannot explain high activity at compound 10d. The activity of 3d ($K_i = 428.36 \mu M$ and MIC = 25 $\mu g/mL$) would depend of hydrogen bind ability of coumarin core.

**Figure 6.** Molecular docking of the most active designed compounds 1d, 2d, 5d and 7d.
3. Experimental

3.1. Synthesis

In our previous papers, synthesis and pharmacological evaluation of the group of 16 substituted potential anticoagulant chromene-2H-one derivatives 1-10c were reported (Scheme 1) [3,4], underlining that two different synthetic approaches used, microwave assisted Knoevenagel condensation (compounds 1-8b) [3] and Hantzsch reaction (compounds 2-10c) [4]. Both methods are efficient in functionalisation of C-3 position in the coumarin moiety. Compounds were characterized by elemental analyses (C, H, N, O and S) with determination of molecular weights by mass spectroscopy (MS). Structural characterisation was performed by infrared spectroscopy (IR), 1H-Nuclear Magnetic Resonance (NMR) and MS spectra.

3.2. Assay for in vitro antimicrobial activity

The antimicrobial activity of synthesized coumarins was measured using the microdilution two-fold method in Mueller-Hinton broth for bacteria and Saboruaud dextrose broth for fungi [19,20] at pH = 7.4. Antimicrobial targets were both Gram positive and negative bacteria and fungi, using wide range of ATCC cultures and clinical isolates [3,4], using Resazurin solution (0.02 mL of 0.05% concentration) [21] for determination of MICs (Table 1).

3.3. Molecular modeling

A data set of 15 compounds has been taken from published articles [3,4]. Preliminary molecular descriptor characterisation of compounds 1-8b has been performed [3] by the PM3 semiempirical method, but those values were not used in this paper. The initial structures were built in Spartan 2002 for Windows [22] then imported in MacroModel [23] to adjust and minimize atom and bond types with the OPLS 2005 force field parameters. The generalized Born/surface area (GB/SA) continuum non solvent model was used to simulate vacuum environment, consequently due to insolubility of the tested compounds in water, but to provide proper optimization according to experiment conditions [3,4]. An extended non-bonded cutoff (van der Waals 8 Å; electrostatic 20 Å) was used. Systematic conformational search on each molecule was performed by 500 step Monte Carlo conformational analysis, 100 steps per rotatable bond, with the energy cutoff generally set to $\Delta E = 10$ kJ/mol above the lowest energy conformation.

Further, the geometry optimization was performed by MOPAC PM6 [24] Hamiltonian semi empirical method imported in Vega ZZ [25], by fixing gradient norm as 0.01, with $\varepsilon = 24.3$ and $\varepsilon = 48.0$, in order to include solubility of compounds 1-8b in ethanol [3], and 2-10c in DMSO [4]. The most stable structures, with determined final heat of formation, were selected as representative conformations in calculation of molecular descriptors in this study.

The CS Gaussian 03 program [26] by density functional theory (DFT) using the B3LYP hybrid functional including 6-31G (d) basis with Mulliken population analysis was applied for partial atomic charge computations of the optimized models.
The virtual log \(P\), Broto log \(P\), lipole, molar refractivity, dipole and ovality of all single molecules were evaluated by VegaZZ software. Steric descriptor values like Connolly Accessible Area (CAA), Connolly Molecular Area (CMA) and Connolly Solvent-Excluded Volume (CSEV) [12,27], were calculated with Chem3D Ultra 10.0/ ChemOffice 2006 software package [28].

Single and multivariable linear regression fits were estimated between –Log MIC values and molecular descriptors and calculated partial charges. Good correlation between biological activity and partial charge indicates functional group as the active one [29]. Origin Pro 8 software [30] used to generate QSAR models by MRA. Cross validation was performed using leave-one-out method.

3.4. Molecular docking

The crystal structure of \(E. coli\) 24 kDa N-terminal domain of DNA gyrase B subunit in complex with clorobiocin from the Brookhaven Protein Data Bank (PDB ID code: 1KZN) was used in docking experiments [31]. Crystallographic waters and inhibitor which were not hydrogen-bonded to the enzyme were removed with Chimera software [32]. Initially, compounds \(1, 3b\) and \(9b\) were used as the ligands for docking; following by docking of the newly designed and optimized structures \(1-10d\). The docking was performed with version 4.0 of AutoDock [33], which combines a rapid energy evaluation through precalculated grids of affinity potentials with a variety of search algorithms to find suitable binding positions for a ligand on given protein. The dimensions of the grids were thus 34 Å x 34 Å x 34 Å, with a spacing of 0.375 Å between the grid points and center grid box coordinates \(x = 17.507, y = 32.5, z = 38.164\). Lamarckian Genetic Algorithm was use for docking, with number of GA runs set to 100 and RMS Cluster Tolerance of 0.5 Å.

4. Conclusions

Based on previously obtained antimicrobial activity of fifteen 4-hydroxycoumarin derivatives, we performed the SAR, QSAR studies on their activity against \(S. aureus\), \(E. coli\) and \(C. albicans\), and molecular docking studies on the antimicrobial activity molecular target. The studies emphasize the important roles of the C-3 carbonyl and thiazole residues in activity, which led to the design of ten new potentially active coumarin antimicrobial agents. The designed compounds have improved predicted \(Ki\) values and antimicrobial activity, which will be confirmed through further synthesis and determination of real antimicrobial activity.

Acknowledgements

This study was financially supported by a Grant No 142025 from the Serbian Ministry of Science.

References and Notes

1. Stein, A.C.; Álvarez, S.; Avancini, C.; Zacchinos, S.; von Poser, G. Antifungal activity of some coumarins obtained from species of \(Pterocaulon\) (Asteraceae). \(J. Ethnopharmacol. 2006\), 107, 95-98.
2. Ojala, T.; Remes, S.; Haansuu, P.; Vuorela, H.; Hiltunen, R.; Haahkela, K.; Vuorela, P. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. \(J. Ethnopharmacol. 2000\), 73, 299-305.
3. Mladenović, M.; Vuković, N.; Niciforović, N.; Sukdolak, S.; Solujić, S. Synthesis and molecular descriptor characterization of novel 4-hydroxy-chromene-2-one derivatives as antimicrobial agents. *Molecules* **2009**, *14*, 1495-1512.

4. Vuković, N.; Sukdolak, S.; Solujić, S.; Milošević, T. Synthesis and antimicrobial evaluation of some novel 2-aminothiayole derivatives of 4-hydroxy-chromene-2-one. *Arch. Pharm. Chem. Life Sci.* **2008**, *341*, 491-496.

5. Kayser, O.; Koldrzízy, H. Antibacterial activity of simple coumarins structural requirements for biological activity. *Z. Naturforch.* **1999**, *54c*, 169-174.

6. Zloh, M.; Bucar, F.; Gibbons, S. Quantum chemical studies on structure activity relationship of natural product polyacetylenes. *Theor. Chem. Acc.* **2007**, *117*, 247-252.

7. Okamoto, A.K.; Gaudio, A.C.; dos Santos Marques, A.; Takahata, Y. QSAR study of inhibition by coumarins of IQ induced mutation in *S. typhimurium* TA98. *J. Mol. Struc. Theochem* **2005**, *725*, 231-238.

8. Basile, A.; Sorbo, S.; Spadaro, V.; Bruno, M.; Maggio, A.; Faraone, N.; Rosselli, S. Antimicrobial and antioxidant activities of coumarins from the roots of *Ferulago campestris* (Apiaceae). *Molecules* **2009**, *14*, 939-952.

9. Widelski, J.; Popova, M.; Graikou, K.; Glowniak, K.; Chinou, I. Coumarins from *Angelica lucida* L.-Antibacterial activities. *Molecules* **2009**, *14*, 2729-2734.

10. Debeljak, Ž.; Škrbo, A.; Jasprica, I.; Mornar, A.; Plečko, V.; Banjanac, M.; Medić-Šaric, M. QSAR Study of antimicrobial activity of some 3-nitrocoumarins and related compounds. *J. Chem. Inf. Model.* **2007**, *47*, 918-926.

11. Hishmit, O. H.; Miky, A.A.J.; Farrag, A.A.; Fadl-Allah, E. M. Synthesis of some coumarin derivatives and their antimicrobial activity. *Arch. Pharm. Res.* **1989**, *12*, 181-185.

12. Sharma, M.C.; Sahu, N.K.; Kohali, D.V.; Chaturvedi, S.C.; Sharma, S. QSAR, synthesis and biological activity studies of some thiazolidines derivatives. *DJNB* **2009**, *4*, 223-232.

13. Lewis, J.R.; Singh, M.P.O.; Smith, V.C.; Skarzynski, T.; Maxwell, A.; Wonacott, J.A.; Wigley, B.D. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines by X-ray crystallography. *EMBO J.* **1996**, *15*, 1412-1240.

14. Šarić-Medić, M.; Mornar, A.; Črnjević-Badovinac, T.; Jasprica, I. Optimization of chromatographic conditions in thin layer chromatography of flavonoids and phenolic acids. *Croat. Chem. Acta* **2004**, *77*, 367-370.

15. Stanchev, S.; Momekov, G.; Jensen, F.; Manolov, I. Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives. *Eur. J. Med. Chem.* **2008**, *43*, 694-706.

16. Cravotto, G.; Tagliapietra, S.; Cappelo, R.; Palmisano, G.; Curini, M.; Boccalini, M. Long-chain 3-acyl-4-hydroxycoumarins: Structure and antibacterial activity. *Arch. Pharm. Chem. Life. Sci.* **2006**, *339*, 129-132.

17. Campos, J.; del Carmen Nunez, M.; Rodriguez, V.; Entrena, A.; Hernandez-Alcoceba, R.; Fernandez, F.; Lalca, I.J., Gallo, M.A.; Espinoza, A. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase. *Eur. J. Med. Chem.* **2001**, *36*, 215-225.
18. Kubinyi, H. The Quantitative Analysis of Structure-Activity Relationships. In *Burger’s medicinal chemistry and drug discovery, principles and practice*, 5th ed.; Wolff, M.E., Ed.; John Wiley & Sons: New York, NY, USA, 1995; Volume 3, pp. 497-571.

19. NCCLS. *Performance standards for antimicrobial susceptibility testing 14th Int. Supplement M100-S14*. Wayne, PA, USA, 2003.

20. Umesh, S; Richardson, P.A.; Kong, P. Hong, C.X. A novel indicator plant to test the hypersensitivity of phytopathogenic bacteria. *J. Microbiol. Meth.* 2008, 72, 95-97.

21. Carter, C.H.; Gaspar, A.J.; Leise, J.M. Resazurin staining of bacterial colonies on membranes filters; Fort Dietrick: Frederick, MD, USA, 1955.

22. Software Spartan 2002 for Windows. Wavefunction, Inc., 18401 Von Karman Ave. Ste. 370, Irvine, CA 92612-8542, USA, 2002.

23. Mohamadi, F.; Richards, N.; Guida, W.; Liskamp, R.; Lipton, M.; Caulfield, C.; Chang, G.; Hendrikson, T.; Still, W. Macromodel an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. *J. Comput. Chem.* 1990, 11, 440-467.

24. Stewart, J.J.P. *MOPAC 2009*. Stewart Computational Chemistry: Colorado Springs, CO, USA, http://www.openMOPAC.net.

25. Pedretti, A.; Villa, A.; Vistoli. G. VEGA: A versatile program to convert, handle and virtualize molecular structure on Windows-based PCs. *J. Mol. Graph. Model.* 2002, 21, 47-49.

26. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Montgomery, J.A., Jr.; Vreven, T.; Kudin, K.N.; Burant, J.C.; Millam, J.M.; Iyengar, S.S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G.A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J.E.; Hratchian, H.P.; Cross, J.B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.E.; Yazyev, O.; Austin, A.J.; Cammi, R.; Pomelli, C.; Ochterski, J.W.; Ayala, P.Y.; Morokuma, K.; Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Zakrzewski, V.G.; Dapprich, S.; Daniels, A.D.; Strain, M.C.; Farkas, O.; Malick, D.K.; Rabuck, A.D.; Raghavachari, K.; Foresman, J.B.; Ortiz, J.V.; Cui, Q.; Baboul, A.G.; Clifford, S.; Cioslowski, J.; Stefanov, B.B.; Liu, G.; Liashenko, A.; Piskor, P.; Komaromi, I.; Martin, R.L.; Fox, D.J.; Keith, T.; Al-Laham, M.A.; Peng, C.Y.; Nanayakkara, A.; Challacombe, M.; Gill, P.M.W.; Johnson, B.; Chen, W.; Wong, M.W.; Gonzalez, C.; Pople, J.A.; *Gaussian 03, Revision C.02*. Gaussian, Inc.: Wallingford, CT, USA.

27. Sharma, P.; Kumar, A.; Upadhyay, S.; Sahu, V.; Singh, J. Synthesis and QSAR modeling of 2-acetyl-2-ethoxycarbonyl-1-[4(4'-aryazo)-phenyl]-N,N-dimethylaminophenyl aziridines as potential antibacterial agents. *Eur. J. Med. Chem.* 2009, 44, 251-259.

28. *Chem3D Ultra 10.0, ChemOffice Ultra*, 2006; Cambridge Scientific Software: CambridgeSoft Corporate Headquarters, 100 Cambridge Park Drive Cambridge, MA 02140, USA, 2006.

29. Nikolic, K.M.; Design and QSAR study of analogs of α-tocopherol with enhanced antiproliferative activity against human breast adenocarcinoma cells. *J. Mol. Graph. Model.* 2008, 26, 868-873.

30. *Origin Pro 8*. OriginLab Corporation: Northampton, MA, USA, 2009.

31. Lafitte, D.; Lamour, V.; Tsvetkov, P.O.; Makarov, A.A.; Klich, M.; Deprez, P.; Moras, D.; Briand, C.; Gilli, R. DNA gyrase interaction with coumarin-based inhibitors: the role of the
hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose. *Biochemistry* **2002**, *41*, 7217-7223.

32. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M., Meng, E.C.; Ferrin, T.E. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem.* **2004**, *25*, 1605-1612.

33. Morris, M.G.; Goodsell, S.D.; Huey, R.; Olson, J.A. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. *J. Comp. Aid. Mol. Des.* **1996**, *10*, 293-304.

*Sample Availability:* Samples of the compounds 1-10c are available from the authors.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).